FOLH1 and prostate cancer: Uptake of the PSMA-based radioligand at the tumour site was expected to occur, given positive results from the use of PSMA as target in prostate cancer, and the observed high expression of PSMA on tumour microvasculature and to a lesser extent on tumour cells of HGG and BM.4